Endovascular treatment versus femoropopliteal bypass surgery for TASC II type C lesions of the superficial femoral artery

Turkish Journal of Vascular Surgery Pub Date : 2021-09-22 DOI:10.9739/tjvs.2022.1067

O. Saydam

{"title":"Endovascular treatment versus femoropopliteal bypass surgery for TASC II type C lesions of the superficial femoral artery","authors":"O. Saydam","doi":"10.9739/tjvs.2022.1067","DOIUrl":null,"url":null,"abstract":"Objectives: In this study, we aimed to compare the outcomes of endovascular treatment (ET) and femoropopliteal artery bypass (FPB) in patients with Trans-Atlantic Inter-Society Consensus (TASC) II type C femoropopliteal lesions. Patients and methods: A total of 149 patients with symptomatic TASC II type C femoropopliteal lesions who underwent invasive treatment between January 2012 and January 2017 were retrospectively analyzed. The patients were divided into two groups as the ET group (n=46; 34 males, 12 females; mean age: 64.3±10.3 years) and the FPB group (n=103; 82 males, 21 females; mean age: 62.9±8.2 years). Primary and secondary patency rates at 6, 12, and 24 months were evaluated. Results: The primary success rates for ET and FPB were 100%. Primary patency at 6, 12, and 24 months were 93.5%, 89.0%, 69.5%, respectively for ET and 86.4%, 81.5%, 72.8%, respectively for FPB (p>0.05). Secondary patency rates at 6, 12, and 24 months were 97.8%, 93.5%, %84.8, respectively for ET and 96.1%, 90.3%, 79.6%, respectively for FPB group (p=0.41). The length of hospital stay was significantly longer in the FPB group (p<0.001). The cost of treatment was significantly higher in the FBP group (p=0.02). Conclusion: In TASC II type C patients, ET is a safe therapeutic option with lower in-hospital stay and treatment expenses and similar primary and secondary patency rates to FPB.","PeriodicalId":23982,"journal":{"name":"Turkish Journal of Vascular Surgery","volume":"33 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Vascular Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9739/tjvs.2022.1067","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Objectives: In this study, we aimed to compare the outcomes of endovascular treatment (ET) and femoropopliteal artery bypass (FPB) in patients with Trans-Atlantic Inter-Society Consensus (TASC) II type C femoropopliteal lesions. Patients and methods: A total of 149 patients with symptomatic TASC II type C femoropopliteal lesions who underwent invasive treatment between January 2012 and January 2017 were retrospectively analyzed. The patients were divided into two groups as the ET group (n=46; 34 males, 12 females; mean age: 64.3±10.3 years) and the FPB group (n=103; 82 males, 21 females; mean age: 62.9±8.2 years). Primary and secondary patency rates at 6, 12, and 24 months were evaluated. Results: The primary success rates for ET and FPB were 100%. Primary patency at 6, 12, and 24 months were 93.5%, 89.0%, 69.5%, respectively for ET and 86.4%, 81.5%, 72.8%, respectively for FPB (p>0.05). Secondary patency rates at 6, 12, and 24 months were 97.8%, 93.5%, %84.8, respectively for ET and 96.1%, 90.3%, 79.6%, respectively for FPB group (p=0.41). The length of hospital stay was significantly longer in the FPB group (p<0.001). The cost of treatment was significantly higher in the FBP group (p=0.02). Conclusion: In TASC II type C patients, ET is a safe therapeutic option with lower in-hospital stay and treatment expenses and similar primary and secondary patency rates to FPB.

查看原文本刊更多论文

股浅动脉TASCⅱ型C型病变的血管内治疗与股腘动脉搭桥手术比较

目的:在本研究中，我们旨在比较跨大西洋跨社会共识(TASC) II型C型股腘动脉病变患者的血管内治疗(ET)和股腘动脉旁路治疗(FPB)的结果。患者和方法:回顾性分析2012年1月至2017年1月间接受有创治疗的149例有症状的TASCⅱ型C型股腘动脉病变患者。患者分为两组:ET组(n=46;男性34人，女性12人;平均年龄:64.3±10.3岁)和FPB组(n=103;男性82人，女性21人;平均年龄:62.9±8.2岁)。评估6、12和24个月的一期和二期通畅率。结果:ET和FPB的初步成功率均为100%。6、12、24个月时，ET的原发性通畅率分别为93.5%、89.0%、69.5%，FPB的原发性通畅率分别为86.4%、81.5%、72.8% (p < 0.05)。ET组第6、12、24个月的二次通畅率分别为97.8%、93.5%、% 84.8%，FPB组分别为96.1%、90.3%、79.6% (p=0.41)。FPB组住院时间明显更长(p<0.001)。FBP组治疗费用显著高于对照组(p=0.02)。结论:在TASC II型C患者中，ET是一种安全的治疗选择，住院时间和治疗费用较低，原发性和继发性通畅率与FPB相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Turkish Journal of Vascular Surgery

CiteScore

0.10

自引率

0.00%

发文量